Track Repligen Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Repligen Corporation RGEN · Stock Open Repligen Corporation in new tab

167.79 USD
P/E
241.97
EPS
-0.21
P/B
4.51
ROE
-0.57
Beta
1.12
Target Price
203.21 USD
Repligen Corporation logo

Repligen Corporation

🧾 Earnings Recap – Q3 2026

Repligen’s shares fell 2.4% after earnings, a roughly flat reaction. The quarter showed solid organic growth and margin expansion, while the key constraint remains capital equipment: revenue declined despite a mid-teens increase in orders, and management said demand has not opened up as quickly as expected.

  • Q3 revenue was $209 million, up 12.5% organically; adjusted operating margin expanded 170 basis points year over year.
  • Consumables grew 20% and services grew more than 20%. Capital equipment orders rose mid-teens and reached a five-year quarterly high, but revenue declined.
  • Management narrowed its full-year organic growth outlook to 12%–13%, with the midpoint up 50 basis points; updated guidance includes $24 million of BioLife revenue after the Q4 close.
  • Biopharma growth was strong across regions, while CDMO revenue declined against a difficult comparison. New modalities were relatively flat, with cell therapy up nearly 30%.
  • Services were 7% of quarterly revenue; systems under service contract increased nearly 40% year to date.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
P/E241.97
EPS-0.21
Book Value36.90
Price to Book4.51
Debt/Equity33.09
% Insiders4.632%
Growth
Revenue Growth0.11%
Earnings Growth-0.66%
Estimates
Forward P/E62.79
Forward EPS2.65
Target Mean Price203.21

DCF valuation

Model fair value for Repligen Corporation (RGEN)
Result
Sign in to run the valuation for RGEN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Buy · mean target 203.21 USD (low 175.00, high 235.00) · as of 12 Nov 2026
Low 175.00
Mean 203.21
High 235.00
Price 167.79
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Repligen Corporation Logo Repligen Corporation Analysis (RGEN)

United States Health Care Official Website Stock

Is Repligen Corporation a good investment? Repligen Corporation (RGEN) is currently trading at 167.79 USD. Market analysts have a consensus price target of 203.21 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 241.97. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Repligen Corporation is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is 2.65.

Investor FAQ

Does Repligen Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Repligen Corporation?

Repligen Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -0.21.

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) RGEN
FRA (Germany) RGN.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion